- Home
- STCN vs ANL Comparison
STCN vs ANL Comparison
Compare STCN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- ANL
- Stock Information
- Founded
- STCN 1986
- ANL 2004
- Country
- STCN United States
- ANL Cayman Islands
- Employees
- STCN N/A
- ANL N/A
- Industry
- STCN Advertising
- ANL
- Sector
- STCN Consumer Discretionary
- ANL
- Exchange
- STCN Nasdaq
- ANL Nasdaq
- Market Cap
- STCN 75.0M
- ANL 72.7M
- IPO Year
- STCN 1994
- ANL 2023
- Fundamental
- Price
- STCN $10.57
- ANL $1.88
- Analyst Decision
- STCN
- ANL Strong Buy
- Analyst Count
- STCN 0
- ANL 2
- Target Price
- STCN N/A
- ANL $9.00
- AVG Volume (30 Days)
- STCN 11.6K
- ANL 9.7K
- Earning Date
- STCN 11-06-2024
- ANL 08-08-2024
- Dividend Yield
- STCN N/A
- ANL N/A
- EPS Growth
- STCN 203.29
- ANL N/A
- EPS
- STCN 3.17
- ANL N/A
- Revenue
- STCN $169,044,000.00
- ANL $5,000,000.00
- Revenue This Year
- STCN N/A
- ANL N/A
- Revenue Next Year
- STCN N/A
- ANL N/A
- P/E Ratio
- STCN $3.34
- ANL N/A
- Revenue Growth
- STCN N/A
- ANL N/A
- 52 Week Low
- STCN $7.36
- ANL $1.86
- 52 Week High
- STCN $13.00
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- STCN 41.19
- ANL 34.71
- Support Level
- STCN $10.54
- ANL $1.89
- Resistance Level
- STCN $11.12
- ANL $2.11
- Average True Range (ATR)
- STCN 0.41
- ANL 0.19
- MACD
- STCN 0.00
- ANL 0.02
- Stochastic Oscillator
- STCN 60.98
- ANL 4.30
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.